Inhibition of RNA function by delivery of inhibitors to animal cells
OwnerDavid L. Lewis, James E. Hagstrom +5inventors
InventorsDavid L. Lewis, James E. Hagstrom, Hans Herweijer, Aaron G. Loomis, Sean D. Monahan, Vladimir S. Trubetskoy, Jon A. Wolff
Life of this patent
Estimating the term…
Abstract
Described is a process for delivering an inhibitor directed against an expressible nucleic acid sequence in a mammal to inhibit RNA function. An RNA function inhibiting sequence that is specific to the expressible nucleic acid sequence in the mammal is made and inserted into a blood vessel in the mammal. The inhibitor is delivered to a cell wherein expression of the nucleic acid sequence is inhibited.
Claims10
A process for delivering an inhibitor directed against an expressible nucleic acid sequence in a mammal to inhibit RNA function, comprising:
- a) making the inhibitor consisting of an RNA function inhibiting sequence that is specific to the expressible nucleic acid sequence in the mammal;
- b) inserting the inhibitor into a vessel in the mammal;
- and,
- c) delivering the function inhibiting sequence to a cell wherein expression of the expressible nucleic acid sequence is inhibited.
A complex for inhibiting nucleic acid expression in a mammal, formed by the process comprising:
- mixing an RNA function inhibitor and at least one compound to form a complex wherein zeta potential of the complex is less negative than the zeta potential of the inhibitor alone.
A complex for inhibiting nucleic acid expression in a mammal formed by the process, comprising:
- a) mixing an RNA function inhibitor with a cationic first layer selected from the group consisting of polycations, proteins, amphipathic compounds, polyampholytes and nonviral vectors;
- wherein the complex has a positive zeta potential;
- and
- b) recharging the complex with an anionic second layer, wherein the zeta potential is less positive than the complex with the first layer alone.
Dependencies are inferred from the claim text.